BioSpace News Archive

Blueberry Therapeutics Limited announces that BB2603, a novel topical terbinafine antifungal product, has met the primary endpoint in the Phase 2b trial in patients with onychomycosis, showing superiority over placebo with a high level of statistical significance.

Telix Pharmaceuticals Limited and Paris-based Mauna Kea Technologies, announce an expansion of the IRiS Alliance[1] through a strategic €6.0 million investment to develop new hybrid pharmaceutical-device products through the combination of Telix’s cancer-targeting agents with Mauna Kea’s Cellvizio® surgical endomicroscopy platform.

Nona Biosciences announced that it has entered into a strategic collaboration with GeneQuantum Healthcare to advance the early discovery of next-generation bioconjugates.

BioNxt Solutions Inc. is pleased to report that it has signed a definitive agreement with a German-based pharmaceutical developer for the acquisition of 100% of the intellectual property rights and joint development of an oral dissolvable drug reformulation using the active pharmaceutical ingredient Cladribine.

Integrum announces that the company has held a pre-submission meeting with the US Food and Drug Administration to discuss the regulatory pathway for the use of Integrum’s OPRA™ Implant System in transhumeral amputations.

iZafe Group AB is pleased to announce that the company’s major shareholders have appointed a nomination committee in consultation with the chairman of the board, Björn Rosengren.

Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of CLK/DYRK kinases, yesterday presented results from a long-term extension study, OA-07 for its knee OA drug candidate, lorecivivint.

Aurinia Pharmaceuticals Inc. announced that the Company’s collaboration partner, Otsuka Pharmaceutical Ltd., filed a new drug application for voclosporin for the treatment of lupus nephritis with the Japanese Ministry of Health, Labour, and Welfare for the manufacture and sale in Japan of voclosporin, a second-generation oral calcineurin inhibitor for the treatment of lupus nephritis.

Annexon, Inc., a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, highlighted portfolio progress and reported third quarter 2023 financial results.

Fortrea, a leading global contract research organization, reported financial results for the third quarter ended September 30, 2023.